JPRN-jRCTs051190071进行中（未招募）2 期
A phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer after adjuvant docetaxel plus S1 therapy for Stage III - OGSG1901
YAMAGUCHI Toshifumi0 个研究点目标入组 40 人开始时间: 2019年11月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) A histopathological diagnosis of adenocarcinoma.
- •2) Patients who are on DS adjuvant chemotherapy after the confirmation of pathological stage III (including ypIII) after radical gastrectomy*1.
- •3) Early recurrence postsurgery: during DS adjuvant chemotherapy*2 or a recurrence within*3 six months after completing therapy*4.
- •4) Age of >20 years.
- •5) Performance status 0 or 1
- •6) Lesions that can be evaluated by imaging according to RECIST 1.1 guidelines or nonmeasurable lesions.
- •7) Laboratory results with the following values within 14 days prior to clinical study registration. Of all values within this 14day period, the most recent will be used for registration. Using the day of registration as the reference point, laboratory results 2 weeks prior to registration can be used as long as the results reflect samples collected on the same day as the registration day.
- •Absolute neutrophil count (ANC): =>1,500/mm3
- •Hemoglobin: =>9.0 g/dL
- •Platelet count: =>100000/mm3
- •AST, ALT: =<100 IU/L
- •(=<200 IU/L in patients with liver metastasis)
- •Total bilirubin: =<1.5 mg/dL (elevated bilirubin associated with grade1 Gilbert's syndrome will be exempted)
- •Serum creatinine: =<1.5 mg/dL, or creatinine clearance: =>40ml/min
- •(estimated creatinine clearance rate using the Cockcroft-Gault formula or creatinine concentration measured after 24-hour urine collection)
- •Urinary protein: =< (1+) on dipstick or routine urinalysis or =>2 g/24 hours after 24-hour urine collection, or urinary protein/creatinine ratio <2
- •PT-INR: =<1.5
- •PTT: =<5 seconds above the ULN
- •(APTT: =<5 seconds above the ULN)
- •8) Written informed consent was obtained from patient after providing a detailed explanation of the clinical study prior to registration.
- •9) HER2 undectable or negative.
- •10) No history of receiving irinotecan or ramucirumab.
- •11) Ability to tolerate chemotherapy or radiation prior to surgery.
- •12) Oral intake possible
- •*1 Gastroesophageal junction adenocarcinoma with R0 resection is also eligible.
- •*2 During adjuvant therapy: After the beginning of the second course of DS therapy (a history of more than one course of DOC).
- •*3 CT scan at 6 months: If CT scan is taken >6 months after the initiation of the final course, because of patient circumstances or the facility, and the patient was diagnosed with recurrence within 4 weeks after the 6-month time point, then the patient was included in the study.
- •*4 After the completion of adjuvant therapy: the end date of adjuvant therapy is defined as 6 weeks after the start date of the final course.
排除标准
- •1.Active multiple primary cancers (synchronous and heterogeneous multiple primary cancers within a 5-year disease-free interval). However, localized treatment resulting in a cure of pathological lesions such as carcinoma in situ or equivalent to intramucosal cancer would not be considered as active multiple primary cancers.
- •2.Symptomatic interstitial pneumonia or pulmonary fibrosis is observed.
- •3.An infection requiring systemic treatment; however, even if HBsAg positive, if the infection is being controlled by nucleoside/nucleotide analogs and serum is confirmed as HBV-DNA negative, then the subject is eligible for registration.
- •4.Body temperature of 38C at the time of registration.
- •5.Pregnant, lactating women, those who may be currently pregnant, or are unwilling to use contraceptives.
- •6.Diagnosed with or manifestations of mental illness demonstrated such that the subject has difficulty in participating in the clinical study.
- •7.Continued systemic steroid administration.
- •8.Presence of a serious complication.
- •9.Anticoagulants are being administered for thromboembolism treatment.
- •10.Uncontrolled hypertension (for example, even with standard oral agents, blood pressure exceeds 150/90 mm Hg).
- •11.Uncontrolled diarrhea affecting daily activities despite adequate treatment.
- •12.Evidence of active bleeding (a history of grade 3 or 4 bleeding within 3 months of receiving the first adjuvant treatment).
- •13.No symptoms consistent with evidence of metastasis to the central nervous system (brain, spinal cord, and meninges).
- •14.Blood transfusion treament within 2 weeks of registration.
- •15.Presence of more than moderate pleural effusion with ascites accumulation.
- •16.Is in the process of enrolling in another interventional clinical study at the time of registration for this clinical study.
- •17.Currently on medication with ataznavir sulfate, for which co-administration with IRI is contraindicated.
- •18.Other situations in which the clinical study physician determines that the subject is an unsuitable candidate.
研究者
相似试验
已完成
不适用
Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancerchemo-refractory gastric cancerJPRN-UMIN000019075Osaka University6
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
已完成
不适用
Phase I study of Ramucirumab and Irinotecan for metastatic gastric cancer previously treated with Fluoropyrimidine with/without Platinum and Taxane.gastric cancerJPRN-UMIN000018606Kobe City Medical Center General Hospital18
已完成
2 期
A phase II study of irinotecan + trastuzumab therapy as a second-line chemotherapy for unresectable advanced or recurrent gastric cancer with HER2 overexpressioJPRN-UMIN000008292Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine20
未知
2 期
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese PatientsGastric CancerJPRN-jRCT2080222292Eli Lilly Japan K.K.